Moderna (MRNA) Expected to Announce Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) is anticipated to post its Q4 2025 results before the market opens on Friday, February 13th. Analysts expect the company to announce earnings of ($2.79) per share and revenue of $611.14 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 13, 2026 at 8:00 AM ET.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $40.51 on Thursday. Moderna has a one year low of $22.28 and a one year high of $55.20. The company has a market capitalization of $15.83 billion, a PE ratio of -5.02 and a beta of 1.32. The stock has a fifty day moving average of $36.67 and a 200-day moving average of $29.74.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares in the company, valued at $115,679.52. This trade represents a 85.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Moderna

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Empowered Funds LLC lifted its stake in Moderna by 2.6% in the fourth quarter. Empowered Funds LLC now owns 13,732 shares of the company’s stock valued at $405,000 after buying an additional 353 shares during the period. Meeder Advisory Services Inc. bought a new position in shares of Moderna during the fourth quarter valued at about $213,000. Inceptionr LLC boosted its stake in shares of Moderna by 104.9% in the 4th quarter. Inceptionr LLC now owns 18,641 shares of the company’s stock worth $550,000 after buying an additional 9,542 shares during the last quarter. Zions Bancorporation National Association UT boosted its position in Moderna by 2,805.3% in the fourth quarter. Zions Bancorporation National Association UT now owns 4,968 shares of the company’s stock worth $147,000 after purchasing an additional 4,797 shares during the last quarter. Finally, Cerity Partners LLC grew its position in Moderna by 123.8% during the fourth quarter. Cerity Partners LLC now owns 27,806 shares of the company’s stock valued at $820,000 after buying an additional 15,383 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on MRNA. BMO Capital Markets raised Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research note on Monday, January 5th. Wall Street Zen raised Moderna from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Bank of America cut their target price on shares of Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research report on Monday, November 10th. Finally, Barclays started coverage on Moderna in a report on Wednesday, January 28th. They set an “equal weight” rating and a $25.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $28.77.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna signed a long‑term strategic memorandum with Mexico to supply respiratory vaccines and transfer mRNA manufacturing technology, which supports multi‑year revenue visibility and local manufacturing upside. Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
• Positive Sentiment: Leadership and media attention remain supportive — high‑profile commentary (e.g., Jim Cramer) continues to spotlight Moderna’s broader pipeline (personalized cancer vaccines and respiratory portfolio), which can sustain investor interest despite short‑term setbacks. Jim Cramer on Moderna
• Neutral Sentiment: Moderna says the RTF does not flag safety or efficacy concerns and that mRNA‑1010 remains under review or accepted in other jurisdictions (EU, Canada, Australia); the company has requested an urgent Type A meeting with FDA to clarify next steps. Reuters: Moderna says US FDA refuses review its influenza vaccine
• Neutral Sentiment: Barclays initiated coverage with an Equal Weight (Neutral) rating and a $25 price target—indicative of tempered Street expectations and signaling that analyst conviction is mixed even as biotech sector outlook improves. Barclays Starts Moderna Neutral
• Negative Sentiment: The FDA issued a Refusal‑to‑File for the mRNA‑1010 Biologics License Application, citing that Moderna’s pivotal trial did not compare the vaccine to the “best‑available” U.S. standard of care for older adults—this creates regulatory uncertainty, delays U.S. commercialization and prompted a sharp intraday share drop. BioPharmaDive: FDA refuses to review Moderna’s mRNA flu vaccine
• Negative Sentiment: Analysts and media warn that the current FDA stance raises execution risk for seasonal vaccine programs and could make future regulatory pathways more onerous—heightening valuation pressure on a company priced for growth beyond COVID vaccines. MarketWatch: Seasonal vaccine work is risky under current FDA

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.